Keiichi Akahoshi

Dr. Keiichi Akahoshi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Journal of Surgical Research
Verified
Journal Article
Closed access
KAKeiichi Akahoshi
Keiichi Akahoshi
HOHiroaki Ono
Hiroaki Ono
MAMasafumi Akasu
Masafumi Akasu
DBDaisuke Ban
Daisuke Ban
AKAtsushi Kudo
Atsushi Kudo
MTMinoru Tanabe
Minoru Tanabe

1 October 2023 in Hepatology Communications
Verified
Journal Article
Open access
MHMegumi Hatano
Megumi Hatano
YAYoshimitsu Akiyama
Yoshimitsu Akiyama
SSShu Shimada
Shu Shimada
KYKohei Yagi
Kohei Yagi
KAKeiichi Akahoshi
Keiichi Akahoshi
Shinji TanakaShinji Tanaka
Shinji Tanaka
Background: NAFLD caused by abnormalities in hepatic lipid metabolism is associated with an increased risk of developing HCC. The molecular mechanisms underlying the progression of NAFLD-related HCC are not fully understood. We investigated the molecular mechanism and role of KDM6B downregulation in NAFLD-related HCC after the KDM6B gene was identified using microarray analysis as commonly downregulated in mouse NAFLD-related HCC and human nonhepatitis B and nonhepatitis C viral-HCC. Methods: The 5-hydroxymethylcytosine levels of KDM6B in HCC cells were determined using glycosylated hydroxymethyl-sensitive PCR. Microarray and chromatin immunoprecipitation analyses using KDM6B-knockout (KO) cells were used to identify KDM6B target genes. Lipotoxicity was assessed using a palmitate-treated cell proliferation assay. Immunohistochemistry was used to evaluate KDM6B expression in human HCC tissues. Results: KDM6B expression levels in HCC cells correlated with the 5-hydroxymethylcytosine levels in the KDM6B gene body region. Gene set enrichment analysis revealed that the lipid metabolism pathway was suppressed in KDM6B-KO cells. KDM6B-KO cells acquired resistance to lipotoxicity (p < 0.01) and downregulated the expression of G0S2, an adipose triglyceride lipase/patatin like phospholipase domain containing 2 (ATGL/PNPLA2) inhibitor, through increased histone H3 lysine-27 trimethylation levels. G0S2 knockdown in KDM6B-expressed HCC cells conferred lipotoxicity resistance, whereas ATGL/PNPLA2 inhibition in the KDM6B-KO cells reduced these effects. Immunohistochemistry revealed that KDM6B expression was decreased in human NAFLD-related HCC tissues (p < 0.001), which was significantly associated with decreased G0S2 expression (p = 0.032). Conclusions: KDM6B-disrupted HCC acquires resistance to lipotoxicity via ATGL/PNPLA2 activation caused by epigenetic downregulation of G0S2 expression. Reduced KDM6B and G0S2 expression levels are common in NAFLD-related HCC. Targeting the KDM6B-G0S2-ATGL/PNPLA2 pathway may be a useful therapeutic strategy for NAFLD-related HCC.

15 April 2018 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
PDF file
YIYoshiya Ishikawa
Yoshiya Ishikawa
DBDaisuke Ban
Daisuke Ban
SWShuichi Watanabe
Shuichi Watanabe
KAKeiichi Akahoshi
Keiichi Akahoshi
HOHiroaki Ono
Hiroaki Ono
MTMinoru Tanabe
Minoru Tanabe

21 March 2021 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
YMYoshiki Murase
Yoshiki Murase
AKAtsushi Kudo
Atsushi Kudo
KAKeiichi Akahoshi
Keiichi Akahoshi
AMAya Maekawa
Aya Maekawa
YIYoshiya Ishikawa
Yoshiya Ishikawa
MTMinoru Tanabe
Minoru Tanabe
Background: Little research is available regarding the treatments combining surgical resection with systemic chemotherapy for advanced pancreatic neuroendocrine neoplasm patients. We retrospectively elucidated whether sunitinib administration before surgery in advanced pancreatic neuroendocrine neoplasm (Pan‐NEN) patients increases survival.Methods: This study included 106 of 326 Pan‐NEN patients with distant metastases and/or unresectable locally advanced tumors who visited our department to receive sunitinib for more than 1 mo during April 2002 to December 2019. Risk factors for overall survival (OS) and disease‐free survival (DFS) were analyzed.Results: The median duration of preoperative sunitinib administration and observation time after sunitinib were 6 and 26.5 mo, respectively. Of 106 patients, 31 (29.2%) underwent surgery following sunitinib administration. Hepatectomy, synchronous hepatopancreatectomy, pancreatectomy, and lymphadenectomy were performed for 13, 12, 5, and 1 patient, respectively. The 5‐y OS rates in the resected and nonresected groups were 88.9% and 14.1%, respectively (P < .001). In the multivariate analysis, the absence of surgical resection following sunitinib (hazard ratio [HR], 13.1; P = .001), poor differentiation (HR, 5.5; P = .007), and bilateral liver metastases (HR, 3.7; P = .048) were independent risk factors for OS, although large liver tumor volumes were more evident in the nonresected group, as patient characteristics. The median DFS was 16.1 mo in 22 patients who underwent R0/1 resections, and risk factors for postoperative recurrence were Ki‐67 index >7.8% (HR, 7.4; P = .02) and R1 resection (HR, 4.4; P = .04).Conclusion: Surgical resection after sunitinib administration improved OS in advanced Pan‐NENs.

26 December 2023 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
KAKeiichi Akahoshi
Keiichi Akahoshi
JSJunichi Shindoh
Junichi Shindoh
MTMinoru Tanabe
Minoru Tanabe
SWShuichi Watanabe
Shuichi Watanabe
HTHayato Takamizawa
Hayato Takamizawa
NKNorihiro Kokudo
Norihiro Kokudo

26 February 2025 in Hepatology
Verified
Journal Article
Open access
TTTomohiko Taniai
Tomohiko Taniai
SSShu Shimada
Shu Shimada
YAYoshimitsu Akiyama
Yoshimitsu Akiyama
MHMegumi Hatano
Megumi Hatano
KYKoya Yasukawa
Koya Yasukawa
Shinji TanakaShinji Tanaka
Shinji Tanaka
Background and Aims: Recent advances in single-cell RNA sequencing (scRNA-seq) technologies have enabled us to clarify gene regulatory networks and immune cell compositions. In this study, the integration of large-scale bulk and single-cell datasets refined HCC classification and shed light on the characteristics of its aggressive subtype. Approach and Results: Single-cell analysis of 228,564 live cells from 6 scRNA-seq datasets identified 5 major clusters of HCC cells with high mitotic activity (cluster 1), activated Wnt/β-catenin signaling (cluster 2), elevated glycolysis (cluster 3), and lipogenesis (clusters 4 and 5). Aggressive HCC subtype defined in bulk RNA-seq analysis of 691 tumor samples comprised a combination of cluster 1 with clusters 3, 4, or 5. Gene regulatory network analysis and gene set enrichment analysis highlighted the essential roles of p53 and MYC in aggressive HCC/cluster 1, and cell composition analysis elucidated T cell depletion as an immune resistance mechanism. In a syngeneic mouse model, Trp53 knockout and MYC overexpression caused high mitotic, tumorigenic, and metastatic phenotypes, characterized by a macrotrabecular pattern, vascular encapsulation, and T cell exclusion. Angiogenesis inhibition disrupted macrotrabecular/vascular encapsulation formation, resulting in T cell recruitment, and its combination with immune checkpoint blockade achieved remission. Conclusions: Single-cell analysis has deepened our understanding of the molecular mechanism and tumor microenvironment in aggressive HCC. The combination of targeting tumor vasculature and blocking immune checkpoints represents a promising therapeutic strategy for this subtype.